{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:19:13Z","timestamp":1780399153590,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.psychres.2011.05.030","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T21:49:06Z","timestamp":1308952146000},"page":"463-468","source":"Crossref","is-referenced-by-count":6,"title":["Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation"],"prefix":"10.1016","volume":"189","author":[{"given":"Louis S.","family":"Matza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Revicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Ascher-Svanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi M.","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Kinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2011.05.030_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/S1461145703003742","article-title":"Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine","volume":"6","author":"Apiquian","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.psychres.2011.05.030_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2011.05.030_bb0015","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1176\/ps.49.4.524","article-title":"A naturalistic study of clinical use of risperidone","volume":"49","author":"Binder","year":"1998","journal-title":"Psychiatric Services"},{"issue":"1","key":"10.1016\/j.psychres.2011.05.030_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"The New England Journal of Medecine"},{"issue":"5","key":"10.1016\/j.psychres.2011.05.030_bb0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80mg\/day and 160mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group","volume":"20","author":"Daniel","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2011.05.030_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/oxfordjournals.schbul.a006993","article-title":"Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies","volume":"29","author":"Davis","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1016\/j.psychres.2011.05.030_bb0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00213-002-1054-x","article-title":"Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale","volume":"162","author":"de Haan","year":"2002","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.psychres.2011.05.030_bb0040","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4088\/JCP.v68n0801","article-title":"Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder","volume":"68","author":"Dunayevich","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2011.05.030_bb0045","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1176\/appi.ajp.158.11.1835","article-title":"Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia","volume":"158","author":"Gitlin","year":"2001","journal-title":"The American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2011.05.030_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychological Medicine"},{"issue":"9618","key":"10.1016\/j.psychres.2011.05.030_bb0055","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.psychres.2011.05.030_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00001504-200201000-00006","article-title":"Psychosocial outcomes in patients with schizophrenia: quality of life and reintegration","volume":"15","author":"Karow","year":"2002","journal-title":"Current Opinion in Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2011.05.030_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1016\/j.psychres.2011.05.030_bb0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.psychres.2011.05.030_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1741-7015-3-21","article-title":"Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs","volume":"3","author":"Liu-Seifert","year":"2005","journal-title":"BMC Medicine"},{"issue":"7","key":"10.1016\/j.psychres.2011.05.030_bb0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4088\/JCP.v62n07a02","article-title":"Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study","volume":"62","author":"Narendran","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.05.030_bb0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"10","key":"10.1016\/j.psychres.2011.05.030_bb0090","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4088\/JCP.v63n1005","article-title":"Clozapine-induced fevers and 1-year clozapine discontinuation rate","volume":"63","author":"Tham","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2011.05.030_bb0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/schbul\/20.2.297","article-title":"Rating of medication influences (ROMI) scale in schizophrenia","volume":"20","author":"Weiden","year":"1994","journal-title":"Schizophrenia Bulletin"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178111004276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178111004276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T01:22:47Z","timestamp":1543713767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178111004276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0165178111004276"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2011.05.030","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}